Antiatherogenic properties of flavonoids: Implications for cardiovascular health

Canadian Journal of Cardiology

Volumn 26, Issue SUPPLA, 2010, Pages 17A-21A

  Mulvihill, Erin E ^a,b   Huff, Murray W ^a,b  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Atherosclerosis; Cardiovascular disease; Dyslipidemia; Endothelium; Flavonoids; Platelets

Indexed keywords

BERBERINE; BLACK TEA EXTRACT; FLAVONOID; LIPOPROTEIN; NARINGENIN; POLYPHENOL; RESVERATROL;

ARTICLE; ATHEROSCLEROSIS; BLOOD FLOW; CACAO; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CELL FUNCTION; DRUG EFFECT; DYSLIPIDEMIA; ENDOTHELIUM CELL; HEALTH; HUMAN; HYPERINSULINEMIA; NONHUMAN; OBESITY; OXIDATION; SOYBEAN; TEA; THROMBOCYTE FUNCTION; ANIMAL; CARDIOVASCULAR DISEASE; CHEMISTRY; DIET; LIPID METABOLISM; REVIEW; RISK FACTOR; VASCULAR ENDOTHELIUM;

ANIMALS; CARDIOVASCULAR DISEASES; DIET; ENDOTHELIUM, VASCULAR; FLAVONOIDS; HUMANS; LIPID METABOLISM; RISK FACTORS;

EID: 77952769142     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(10)71056-4     Document Type: Article

References (55)

1. Hackam DG, Anand SS. Emerging risk factors for atherosclerotic vascular disease: A critical review of the evidence. JAMA 2003;290:932-40.
2. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: A meta-analysis of randomized controlled trials. JAMA 1999;282:2340-6.
3. Yusuf S. From the HOPE to the ONTARGET and the TRANSCEND studies: Challenges in improving prognosis. Am J Cardiol 2002;89:18A-25A; discussion 25A-26A.
4. Yusuf S. Two decades of progress in preventing vascular disease. Lancet 2002;360:2-3.
5. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459-67.
6. Scalbert A, Williamson G. Dietary intake and bioavailability of polyphenols. J Nutr 2000;130:2073S-85S.
7. Feskens EJ, Kromhout D. Hyperinsulinemia, risk factors, and coronary heart disease. The Zutphen Elderly Study. Arterioscler Thromb 1994;14:1641-7.
8. Hertog MG, Feskens EJ, Hollman PC, Katan MB, Kromhout D. Dietary antioxidant flavonoids and risk of coronary heart disease: The Zutphen Elderly Study. Lancet 1993;342:1007-11.
9. Huxley RR, Neil HA. The relation between dietary flavonol intake and coronary heart disease mortality: A meta-analysis of prospective cohort studies. Eur J Clin Nutr 2003;57:904-8.
10. Bazzano LA. The high cost of not consuming fruits and vegetables. J Am Diet Assoc 2006;106:1364-8.
11. Miura K, Greenland P, Stamler J, Liu K, Daviglus ML, Nakagawa H. Relation of vegetable, fruit, and meat intake to 7-year blood pressure change in middle-aged men: The Chicago Western Electric Study. Am J Epidemiol 2004;159:572-80.
12. Tohill BC, Seymour J, Serdula M, Kettel-Khan L, Rolls BJ. What epidemiologic studies tell us about the relationship between fruit and vegetable consumption and body weight. Nutr Rev 2004;62:365-74.
13. Feskens EJ, Virtanen SM, Rasanen L, et al. Dietary factors determining diabetes and impaired glucose tolerance. A 20-year follow-up of the Finnish and Dutch cohorts of the Seven Countries Study. Diabetes Care 1995;18:1104-12.
14. Hooper L, Kroon PA, Rimm EB, et al. Flavonoids, flavonoid-rich foods, and cardiovascular risk: A meta-analysis of randomized controlled trials. Am J Clin Nutr 2008;88:38-50.
15. Manach C, Williamson G, Morand C, Scalbert A, Remesy C. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr 2005;81:230S-42S.
16. Aherne SA, O'Brien NM. Mechanism of protection by the flavonoids, quercetin and rutin, against tert-butylhydroperoxideand menadione-induced DNA single strand breaks in Caco-2 cells. Free Radic Biol Med 2000;29:507-14.
17. Consigny PM. Pathogenesis of atherosclerosis. AJR Am J Roentgenol 1995;164:553-8.
18. De Caterina R, Libby P, Peng HB, et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995;96:60-8.
19. Avogaro A, de Kreutzenberg SV, Fadini G. Endothelial dysfunction: Causes and consequences in patients with diabetes mellitus. Diabetes Res Clin Pract 2008;82(Suppl 2):S94-S101.
20. Mugge A, Brandes RP, Boger RH, et al. Vascular release of superoxide radicals is enhanced in hypercholesterolemic rabbits. J Cardiovasc Pharmacol 1994;24:994-8.
21. Puddu P, Puddu GM, Cravero E, Rosati M, Muscari A. The molecular sources of reactive oxygen species in hypertension. Blood Press 2008;17:70-7.
22. Benavente-Garcia O, Castillo J. Update on uses and properties of citrus flavonoids: New findings in anticancer, cardiovascular, and anti-inflammatory activity. J Agric Food Chem 2008;56:6185-205.
23. Darley-Usmar V, Wiseman H, Halliwell B. Nitric oxide and oxygen radicals: A question of balance. FEBS Lett 1995;369:131-5.
24. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999;340:115-26.
25. Afanas'ev IB, Dorozhko AI, Brodskii AV, Kostyuk VA, Potapovitch AI. Chelating and free radical scavenging mechanisms of inhibitory action of rutin and quercetin in lipid peroxidation. Biochem Pharmacol 1989;38:1763-9.
26. Zhang H, Zhang J, Ungvari Z, Zhang C. Resveratrol improves endothelial function: Role of TNFα and vascular oxidative stress. Arterioscler Thromb Vasc Biol 2009;29:1164-71.
27. Sanchez M, Lodi F, Vera R, et al. Quercetin and isorhamnetin prevent endothelial dysfunction, superoxide production, and overexpression of p47phox induced by angiotensin II in rat aorta. J Nutr 2007;137:910-5.
28. Jochmann N, Lorenz M, Krosigk A, et al. The efficacy of black tea in ameliorating endothelial function is equivalent to that of green tea. Br J Nutr 2008;99:863-8.
29. Hodgson JM, Puddey IB, Burke V, Watts GF, Beilin LJ. Regular ingestion of black tea improves brachial artery vasodilator function. Clin Sci (Lond) 2002;102:195-201.
30. Grassi D, Desideri G, Necozione S, et al. Blood pressure is reduced and insulin sensitivity increased in glucose-intolerant, hypertensive subjects after 15 days of consuming high-polyphenol dark chocolate. J Nutr 2008;138:1671-6.
31. Moore KJ, Freeman MW. Scavenger receptors in atherosclerosis: Beyond lipid uptake. Arterioscler Thromb Vasc Biol 2006;26:1702-11.
32. Whitman SC, Kurowska EM, Manthey JA, Daugherty A. Nobiletin, a citrus flavonoid isolated from tangerines, selectively inhibits class A scavenger receptor-mediated metabolism of acetylated LDL by mouse macrophages. Atherosclerosis 2005;178:25-32.
33. Hayek T, Fuhrman B, Vaya J, et al. Reduced progression of atherosclerosis in apolipoprotein E-deficient mice following consumption of red wine, or its polyphenols quercetin or catechin, is associated with reduced susceptibility of LDL to oxidation and aggregation. Arterioscler Thromb Vasc Biol 1997;17:2744-52.
34. Aviram M, Volkova N, Coleman R, et al. Pomegranate phenolics from the peels, arils, and flowers are antiatherogenic: Studies in vivo in atherosclerotic apolipoprotein e-deficient (E 0) mice and in vitro in cultured macrophages and lipoproteins. J Agric Food Chem 2008;56:1148-57.
35. Fuhrman B, Buch S, Vaya J, et al. Licorice extract and its major polyphenol glabridin protect low-density lipoprotein against lipid peroxidation: In vitro and ex vivo studies in humans and in atherosclerotic apolipoprotein E-deficient mice. Am J Clin Nutr 1997;66:267-75.
36. Fuhrman B, Lavy A, Aviram M. Consumption of red wine with meals reduces the susceptibility of human plasma and low-density lipoprotein to lipid peroxidation. Am J Clin Nutr 1995;61:549-54.
37. Do GM, Kwon EY, Kim HJ, et al. Long-term effects of resveratrol supplementation on suppression of atherogenic lesion formation and cholesterol synthesis in apo E-deficient mice. Biochem Biophys Res Commun 2008;374:55-9.
38. Mackness MI, Harty D, Bhatnagar D, et al. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis 1991;86:193-9.
39. Li RW, Theriault AG, Au K, et al. Citrus polymethoxylated flavones improve lipid and glucose homeostasis and modulate adipocytokines in fructose-induced insulin resistant hamsters. Life Sci 2006;79:365-73.
40. Kong W, Wei J, Abidi P, et al. Berberine is a novel cholesterollowering drug working through a unique mechanism distinct from statins. Nat Med 2004;10:1344-51.
41. Baur JA, Pearson KJ, Price NL, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006;444:337-42.
42. Lagouge M, Argmann C, Gerhart-Hines Z, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006;127:1109-22.
43. Choi JS, Yokozawa T, Oura H. Improvement of hyperglycemia and hyperlipemia in streptozotocin-diabetic rats by a methanolic extract of Prunus davidiana stems and its main component, prunin. Planta Med 1991;57:208-11.
44. Borradaile NM, de Dreu LE, Huff MW. Inhibition of net HepG2 cell apolipoprotein B secretion by the citrus flavonoid naringenin involves activation of phosphatidylinositol 3-kinase, independent of insulin receptor substrate-1 phosphorylation. Diabetes 2003;52:2554-61.
45. Borradaile NM, de Dreu LE, Barrett PH, Behrsin CD, Huff MW. Hepatocyte apoB-containing lipoprotein secretion is decreased by the grapefruit flavonoid, naringenin, via inhibition of MTPmediated microsomal triglyceride accumulation. Biochemistry 2003;42:1283-91.
46. Borradaile NM, de Dreu LE, Barrett PH, Huff MW. Inhibition of hepatocyte apoB secretion by naringenin: Enhanced rapid intracellular degradation independent of reduced microsomal cholesteryl esters. J Lipid Res 2002;43:1544-54.
47. Allister EM, Borradaile NM, Edwards JY, Huff MW. Inhibition of microsomal triglyceride transfer protein expression and apolipoprotein B100 secretion by the citrus flavonoid naringenin and by insulin involves activation of the mitogen-activated protein kinase pathway in hepatocytes. Diabetes 2005;54:1676-83.
48. Allister EM, Mulvihill EE, Barrett PH, Edwards JY, Carter LP, Huff MW. Inhibition of apoB secretion from HepG2 cells by insulin is amplified by naringenin, independent of the insulin receptor. J Lipid Res 2008;49:2218-29.
49. Mulvihill EE, Allister EM, Sutherland BG, et al. Naringenin prevents dyslipidemia, apoB overproduction and hyperinsulinemia in LDL-receptor null mice with diet-induced insulin resistance. Diabetes 2009;58:2198-210.
50. Rosenblat M, Volkova N, Coleman R, Aviram M. Pomegranate byproduct administration to apolipoprotein e-deficient mice attenuates atherosclerosis development as a result of decreased macrophage oxidative stress and reduced cellular uptake of oxidized low-density lipoprotein. J Agric Food Chem 2006;54:1928-35.
51. Berrougui H, Grenier G, Loued S, Drouin G, Khalil A. A new insight into resveratrol as an atheroprotective compound: Inhibition of lipid peroxidation and enhancement of cholesterol efflux. Atherosclerosis 2009;207:420-7.
52. Mulvihill EE, Assini JM, Sutherland BG, et al. Naringenin decreases progression of atherosclerosis by improving dyslipidemia in high-fat-fed low-density lipoprotein receptor-null mice. Arterioscler Thromb Vasc Biol 2010. (In press)
53. Lee IM, Cook NR, Gaziano JM, et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: The Women's Health Study: A randomized controlled trial. JAMA 2005;294:56-65.
54. Lonn E, Bosch J, Yusuf S, et al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: A randomized controlled trial. JAMA 2005;293:1338-47.
55. Hollman PC, Katan MB. Dietary flavonoids: Intake, health effects and bioavailability. Food Chem Toxicol 1999;37:937-42.